← Browse by Condition
Medical Condition

adenoid cystic carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for adenoid cystic carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — adenoid cystic carcinoma Clinical Trials

How many clinical trials are currently recruiting for adenoid cystic carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for adenoid cystic carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for adenoid cystic carcinoma?
adenoid cystic carcinoma research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a adenoid cystic carcinoma clinical trial?
Eligibility criteria for adenoid cystic carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Top Sponsors
Novelty Nobility, Inc. 1 trial
Eye & ENT Hospital of Fudan University 1 trial
Glenn J. Hanna 1 trial

Recruiting Clinical Trials

NCT06805825 Phase 1
Recruiting
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Enrollment
67 pts
Location
United States
Sponsor
Novelty Nobility, Inc.
View Trial →
NCT07522879 Phase 2
Recruiting
A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma
Enrollment
40 pts
Location
China
Sponsor
Eye & ENT Hospital of Fudan Un...
View Trial →
NCT06805617 Phase 2
Recruiting
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Enrollment
35 pts
Location
United States
Sponsor
Glenn J. Hanna
View Trial →

Related Conditions

gastrointestinal stromal tumors (1) small cell lung cancer (1) uveal melanoma (1) neuroendocrine tumors (1) chromophobe renal cell carcinoma (1) clear cell renal cell carcinoma (1) sinonasal carcinoma (1) salivary gland cancer (1) advanced salivary gland carcinoma (1) metastatic salivary gland cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology